TrialPath

51 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

40 studies on the map

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) — Mayo Clinic in Arizona, ScottsdaleSafety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant — University of Cincinnati, CincinnatiA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort — Research Site, GlendaleEmpagliflozin Treatment in Kidney Transplant Recipients — Edward Hines Jr. VA Hospital, Hines, IL, HinesStudy of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma — Stanford, Palo AltoA Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006) — Panax Clinical Research ( Site 0003), Miami LakesConcomitant Renal and Urinary Bladder Allograft Transplantation — Mayo Clinic, RochesterA Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function — Floridian Clinical Research, LLC, Miami LakesA Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease — Floridian Clinical Research, Miami LakesPioglitazone to Reduce Sympathetic Overactivity in CKD Patients — University of Texas at Arlington, ArlingtonStudy to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD — Northwestern Memorial Hospital, ChicagoSafety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease — Quotient Sciences Sea View, MiamiOral Iron in Children With Chronic Kidney Disease — Weill Cornell Medicine / New York Presbyterian Hospital, New YorkA Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered by Intravenous Infusion Investigational Intervention in Participants Aged 35 to 75 Years of Age With Chronic Kidney Disease (CKD) — SouthCoast Research Center, Inc., MiamiSleep, Dreaming, and Virtual Reality for Mental Health — Northwestern University, EvanstonMechanism of SGLT2 Inhibition in the Kidney — University of Michigan, Ann ArborSubclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease — Brigham and Women's Hospital, BostonSafety of Short-course of NSAIDs in Pediatric Patients With CKD — Children's Hospital Colorado, AuroraDelayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants — UCLA, Los AngelesEffect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease — Northwestern University, ChicagoBZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants — Ohio State University Comprehensive Cancer Center, ColumbusEffect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD — Washington DC Veterans Affairs Medical Center (688), Washington D.C.AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses — Mayo Clinic in Florida, JacksonvilleOral Intradialytic Amino Acid Supplementation to Vitalize End-stage Kidney Disease Patients on Hemodialysis — The University of Texas Health Science Center at San Antonio, San AntonioSympatholysis in Chronic Kidney Disease — Atlanta VA Medical Center, DecaturAdia Med of Winter Park LLC Chronic Kidney Disease Research Study — Adia Med Of Winter Park, Winter ParkStudy to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD — New York University Langone Health, New YorkFeasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease — Ann & Robert H. Lurie Children's Hospital of Chicago, ChicagoBreakthrough - T1DM and Chronic Kidney Disease — The University of Chicago, ChicagoAcute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A) — University of Cincinnati, CincinnatiProcesses and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression — Laureate Institute for Brain Research, TulsaAcceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesACT for Individuals With MNCD and Their Care Partners — Texas Tech University Plaza Building, LubbockOpen-Label Psilocybin Study in Transdiagnostic Population — Connecticut Mental Health Center - Yale School of Medicine, New HavenCannabidiol Effects on Learning and Anxiety — University of Connecticut, StorrsPharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE) — University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience, CincinnatiSelf-Adjusted Nitrous Oxide: A Feasibility Study in the Setting of Vasectomy — Beth Israel Deaconess Medical Center, BostonThe Impact of Focused Ultrasound Thalamotomy of the Anterior Nucleus for Focal-Onset Epilepsy on Anxiety — The Ohio State University, ColumbusTrial With the Treatment of Sertraline in Youth With Generalized, Separation and/or Social Anxiety Disorders. — University of Cincinnati, CincinnatiFeasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer — Cedars-Sinai Medical Center, Los Angeles